Kathleen Elizabeth Corey MD
Hepatology & Liver Transplantation
Associate Professor of Medicine, Harvard Medical School. Faculty Mass General
Join to View Full Profile
55 Fruit StreetWang 5Boston, MA 02114
Phone+1 617-726-5925
Fax+1 617-724-5997
Dr. Corey is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Kathleen Corey is a gastroenterologist in Boston, MA and is affiliated with Massachusetts General Hospital. She received her medical degree from Duke University School of Medicine and has been in practice 14 years. She specializes in hepatology & liver transplantation and is board certified in hepatology and transplant hepatology. She has more than 100 publications and over 500 citings.
Education & Training
Harvard Medical SchoolMasters, Medical Science, Clinical investigation , 2015 - 2016
Mass General Brigham/Massachusetts General HospitalFellowship, Transplant Hepatology, 2010 - 2011- Mass General Brigham/Massachusetts General HospitalFellowship, Gastroenterology, 2006 - 2010
- Mass General Brigham/Massachusetts General HospitalChief Residency, Internal Medicine, 2007 - 2008
- Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2003 - 2006
University of North Carolina at Chapel Hill School of MedicineMPH, Epidemiology , 2002 - 2003
Duke University School of MedicineClass of 2003
Certifications & Licensure
MA State Medical License 2005 - 2027
American Board of Internal Medicine Gastroenterology- American Board of Internal Medicine Transplant Hepatology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Impact of Weight Loss Surgery in Adolescents With NAFLD Start of enrollment: 2014 Sep 15
- Characterization and Technical Evaluation of cT1 for NASH (CATE-NASH) Start of enrollment: 2021 Jan 28
- Intermittent Fasting for NAFLD in Adults Start of enrollment: 2022 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- Quantitative MRI for Monitoring Metabolic Dysfunction-Associated Steatotic Liver Disease: A Test-Retest Repeatability Study.Cayden Beyer, Anneli Andersson, Elizabeth Shumbayawonda, Naim Alkhouri, Ami Banerjee
Journal of Magnetic Resonance Imaging. 2025-04-01 - Prediagnostic Plasma Metabolites Are Associated with Incident Hepatocellular Carcinoma: A Prospective Analysis.Robert M Wilechansky, Prasanna K Challa, Xijing Han, Xinwei Hua, Alisa K Manning
Cancer Prevention Research. 2025-04-01 - Case 9-2025: A 59-Year-Old Man with Hepatocellular Carcinoma.Kathleen E Corey, David M Dudzinski, Alexander R Guimaraes, Mari Mino-Kenudson
The New England Journal of Medicine. 2025-03-27
Journal Articles
- The Great Opportunity: Cultivating Scientific Inquiry in Medical ResidencyMarc N Wein, Michael K Mansour, Jatin M Vyas, Jayaraj Rajagopal, Mark C Fishman, Kathleen E Corey, Caroline L Sokol, Katrina A Armstrong, The Journal of Infectious Diseases
- Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in HIV/HCV CoinfectionMa Somsouk, Eoin R Feeney, Raymond T Chung, Steven Deeks, Annie J Kruger, Ricard Masia, Kathleen E Corey, Esperance A Schaefer, The Journal of Infectious Diseases
Authored Content
- The Nonalcoholic Fatty Liver Disease (NAFLD) Fibrosis Score, Cardiovascular Risk Stratification and a Strategy for Secondary Prevention with EzetimibeMay 2018
Press Mentions
Fatty Liver Disease Symptoms Are Often ‘Silent’: MDs Explain What to Look ForJuly 24th, 2024- Fatty Liver Disease: Bleeding Gums Could Indicate Your Risk of the Deadly ConditionFebruary 26th, 2021
Machine Learning Used to Surpass MELD in Assessing Liver DiseaseOctober 26th, 2017- Join now to see all
Grant Support
- Estrogen Administration for the Treatment of NASH in Postmenopausal WomenMASSACHUSETTS GENERAL HOSPITAL2021–2026
- Estrogen Administration for the Treatment of NASH in Postmenopausal WomenMASSACHUSETTS GENERAL HOSPITAL2021–2026
- Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular RiskMASSACHUSETTS GENERAL HOSPITAL2018–2025
- Interactions Between Hepatitis C And Serum Lipid HomeostasisNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2010
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
